Loading clinical trials...

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer | Clinical Trials | Clareo Health

RECRUITINGNA

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

Phase 2 Trial of Ablative MRI-guided Stereotactic Body Radiation Therapy and Tumor Treating Fields for Locally Advanced Pancreas Cancer

NCT05679674•Baptist Health South Florida

View on ClinicalTrials.gov

Summary

The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR therapy once per day for five days and use the TTF system for at least 18 hours per day starting on the first day of SABR until the tumor progresses or severe toxicity develops.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas. Locally advanced pancreas cancer as per National Comprehensive Cancer Network (NCCN) Guidelines.
•Regional lymph node involvement is permitted if able to be treated with radiation therapy.
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
•At least 3 months of prior FOLFIRINOX, modified FOLFIRINOX, and/or gemcitabine/nab-paclitaxel delivered for pancreas cancer without evidence of distant progression on restaging radiographic studies.
•Carbohydrate antigen 19-9 (CA 19-9) ≤500 U/mL on most recent assessment prior to study enrollment.
•Adequate normal organ and marrow function as defined below:
•i. Hemoglobin ≥8.0 g/dL that may be achieved with transfusion ii. Absolute neutrophil count (ANC) ≥1500 per mm\^3 iii. Platelet count ≥60,000 per mm\^3 iv. Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN) v. AST (SGOT)/ALT (SGPT) ≤3 x institutional ULN
•People of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a participant become pregnant or suspect they are pregnant while participating in this study, they must inform the treating physician immediately.
•Able to operate the tumor treating field (NovoTTF-100L) system independently or with assistance.
•All participants must sign written informed consent.

Exclusion Criteria

•Distant metastasis from pancreas cancer.
•Contraindication to having a magnetic resonance imaging (MRI) scan.
•Prior abdominal radiation therapy.
•History of any primary malignancy with the exception of:
•1. Malignancy treated with curative intent and with no known active disease for at least 3 years before enrollment on this study.
•2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
•3. Adequately treated carcinoma in situ without evidence of disease (i.e., cervical carcinoma in situ; superficial bladder cancer).
•Any unresolved toxicity (Common Terminology Criteria for Adverse Events version 5.0 \> grade 2) from previous anti-cancer therapy. Participants with irreversible toxicity that is not reasonably expected to worsen by treatment on this study are permitted to enroll on this study.
•History of inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).
•Any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of patient safety or study results.
+4 more criteria

Locations (1)

Miami Cancer Institute at Baptist Health, Inc.

Miami, Florida, United States

Key Dates

Start Date

September 21, 2023

Primary Completion Date

June 1, 2027

Completion Date

June 1, 2027

Last Updated

January 12, 2026

Enrollment

ESTIMATED participants

Conditions

Pancreas CancerLocally AdvancedLocally Advanced Pancreatic Adenocarcinoma

Interventions

Stereotactic Ablative Body Radiation (SABR)

RADIATION

Tumor Treating Fields (TTF)

DEVICE

Contacts

Michael Chuong, M.D.

CONTACT

(786) 596-2000 MichaelChu@baptisthealth.net

Carla Salazar

CONTACT

(786) 595-7073 Carla.SalazarMonteagudo@baptisthealth.net

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)